Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 5
Submit an article Journal homepage
49
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?

POOLE-WILSON PA, LUBSEN J, KIRWAN BA et al.: Effect of long-acting nifedipine on mortality in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 364:849-857 [1], and NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomised controlled trial. JAMA (2004) 292:2217-2225 [2].

Sheila A Doggrell Doggrell Biomedical Communications
Pages 831-834 | Published online: 10 May 2005

Bibliography

  • POOLE-WILSON PA, LUBSEN J, KIRWAN BA et al.: Effect of long-acting nifedipine on mortality in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 364:849–857.
  • NISSEN SE, TUZCU EM, LIBBY P et al:Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292:2217–222.
  • FURBERG CD, PSATY BM, MEYER JV:Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation (1995) 92:1326–1331.
  • PSATY BM, HECKBERT SR, KOEPSELL TD et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 274:620–625.
  • STASON WB, SCHMID CH, NIEDZWIECKI D et al: Safety of nifedipine in patients with hypertension: a meta analysis. Hypertension (1997) 30:7–14.
  • STASON WB, SCHMID CH, NIEDZWIECKI D et al: Safety of nifedipine in angina pectoris: a meta analysis. Hypertension (1999) 33:24–31.
  • THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. N Engl. I Med. (2000) 342:145–153.
  • THE EUROPEAN TRIAL ON REDUCTION OF CARDIAC EVENTS WITH PERINDOPRIL IN STABLE CORONARY ARTERY DISEASE INVESTIGATORS. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782–788.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.